Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by MediWound Ltd.
< Previous
1
2
Next >
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
December 17, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update
November 26, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Third Quarter 2024 Financial Results
November 12, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers
October 10, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
October 08, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
August 15, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
August 14, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
August 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Second Quarter 2024 Financial Results
August 02, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
July 29, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
July 16, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces $25 Million Strategic Private Placement Financing
July 15, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
May 29, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report First Quarter 2024 Financial Results
May 22, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
April 25, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 21, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
February 12, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound to Participate in Two Upcoming Investor Conferences
February 05, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
January 09, 2024
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
December 28, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
December 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Reports Third Quarter 2023 Financial Results and Provides Company Update
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer
November 21, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
ENLV
MDWD
MediWound to Report Third Quarter 2023 Financial Results
November 14, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Receives Positive CHMP Opinion Recommending Approval for NexoBrid® to Treat Pediatric Patients
November 13, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces a Collaboration with PolyMedics Innovations (PMI) for NexoBrid® Distribution in Europe
November 08, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MediWound Announces Collaboration with 3M on EscharEx® Phase III Study
October 11, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
MMM
MediWound Deploys NexoBrid® for Emergency Supply
October 09, 2023
From
MediWound Ltd.
Via
GlobeNewswire
Tickers
MDWD
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.